MVA/HIV62B Vaccine
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV Infections
Phase 1
Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications
WithdrawnNCT01909414
Updated: 2021-11-11
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
CompletedNCT02852005
Start: 2017-01-31End: 2019-10-29Updated: 2022-08-08
Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
WithdrawnNCT04041674
Start: 2022-03-01End: 2023-05-31Updated: 2021-10-15